CJC-1295 DAC
$89.94
Select options
Global Peptides supplies this combined research preparation to laboratories across Australia, pairing two independently studied compounds within a single lyophilised vial for comparative laboratory work.
This BPC-157 and TB-500 blend brings together a pentadecapeptide derived from a gastric protective protein sequence with a synthetic heptapeptide linked to the actin regulating segment of Thymosin Beta-4. Each compound carries its own separate research record, and no dedicated study has evaluated the pair together as a combined formulation, so this preparation does not carry an established joint research profile.
Each batch is produced under controlled manufacturing conditions and undergoes independent laboratory verification, supporting consistent, repeatable results across analytical testing. A Certificate of Analysis is available on request for every order.
Many researchers ask what this blend contains and whether the two compounds have been studied together.
This preparation combines two mechanistically distinct research peptides within one vial. BPC-157 is a synthetic pentadecapeptide of 15 amino acids, referenced in the literature for its stability in low pH environments and its association with nitric oxide signalling, angiogenesis and cytoprotective research models. TB-500 is a synthetic heptapeptide built on the Ac-LKKTETQ sequence, referenced for its interaction with G-actin and its relevance to cell migration and angiogenesis research.
Because each compound has an independent literature, researchers typically evaluate the two on their own terms rather than assuming a validated combined effect. Also referenced in supplier listings as the BPC-157 + TB-500 peptide combination, this preparation is intended for comparative laboratory investigation of both compounds side by side.
Within controlled laboratory settings, research connected to this combination commonly touches on areas such as:
These points reflect laboratory observation of each compound's separate literature only and are not intended as claims about therapeutic outcomes or combined efficacy.
Laboratories comparing tissue related and migration focused research often reference this preparation because it allows both compounds to be studied side by side within a single analytical workflow, rather than requiring two separate orders.
Some researchers also list this preparation as a TB 500 BPC 157 blend when comparing supplier catalogues, though the underlying compounds and research profile remain the same regardless of naming order. Researchers comparing options across related compounds can explore the full peptides category for additional research materials.
Laboratories searching for a BPC 157 & TB 500 blend in Australia can access verified material through Global Peptides, supported by transparent documentation and confirmed purity levels for each compound.
Researchers who want to source this preparation for laboratory projects gain access to batch specific Certificates of Analysis, HPLC verification and secure ordering processes designed for research institutions.
Global Peptides offers consistent quality control at every stage of supply, and researchers can browse our catalog to view other research compounds available alongside this combined preparation.
This BPC 157 TB 500 peptide blend is supplied strictly for laboratory and scientific research purposes and is not approved for consumption, therapeutic use or clinical application outside of a qualified research setting. It is not intended for use in humans or animals in any form, and no dosing, administration or usage guidance is provided. Neither compound has an established combined research profile, and all information presented here is drawn from each compound's separate, controlled, non-clinical laboratory research. It does not represent a claim about this product.
